Search results for " Guidelines as Topic"

showing 10 items of 318 documents

Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

2018

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline.…

Liver Cirrhosishepatitis C virusmedicine.medical_treatment030232 urology & nephrologylcsh:RC870-923medicine.disease_causecryoglobulinemialiver testingantivirals0302 clinical medicinesystematic reviewMedicineInfection controlKidney transplantationKDIGOCross Infectionhemodialysisnosocomial transmissionvirus diseasesHepatitis CHepatitis Cinfection controlNephrologyPractice Guidelines as Topic030211 gastroenterology & hepatologyHemodialysisguidelineGlomerular Filtration Ratemedicine.medical_specialtyHepatitis C viruskidney transplantationAntiviral Agents03 medical and health sciencesRenal DialysisDisease Transmission InfectiousHumansRenal Insufficiency ChronicIntensive care medicineglomerular diseasesdirect-acting antiviralsDialysisbusiness.industryscreeningGuidelinelcsh:Diseases of the genitourinary system. Urologymedicine.diseaseKidney Transplantationdialysisbusinesschronic kidney diseaseKidney diseaseKidney International
researchProduct

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice.

2020

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main …

Liver Cirrhosismedicine.medical_specialtyBest practicePsychological interventionMEDLINEDiseasedigestive systemRisk Assessment03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineHumansMass ScreeningIntensive care medicinebusiness.industryPublic healthGastroenterologymedicine.diseaseAdvanced fibrosis Best practice Identification NAFLD NASHdigestive system diseasesEarly Diagnosis030220 oncology & carcinogenesisPractice Guidelines as TopicDisease Progression030211 gastroenterology & hepatologyIdentification (biology)businessAlgorithmsJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Malnutrition in elderly: Social and economic determinants

2013

Abstract: Malnutrition occurs frequently in the frailest groups of the population, especially in people who are on a low income and elderly subjects, overall if they are institutionalized. The aim of this study was to assess the prevalence of malnutrition in a sample of elderly people living in different settings and to identify the determinants of malnutrition. Methods: A total of 718 subjects, 472 females (F) and 246 males (M), were recruited from nursing homes or were free living in three different regions in Italy. Nutritional status, depression, social, functional and cognitive status, were evaluated. Results: According to the Mini Nutritional Assessment (MNA), a high prevalence of mal…

Low incomeGerontologyMaleSettore MED/09 - Medicina InternapovertyMalnutrition elderly poverty.PopulationNutritional StatusMedicine (miscellaneous)Guidelines as TopicelderlyGeriatric populationRisk Factorspoverty; elderly; malnutrition80 and overPrevalenceElderly peopleMedicineHumanseducationGeriatric AssessmentDepression (differential diagnoses)AgedAged 80 and overeducation.field_of_studyNutrition and Dieteticsbusiness.industryMalnutritionNutritional statuselderly; Malnutrition; poverty; Aged; Aged 80 and over; Female; Geriatric Assessment; Guidelines as Topic; Humans; Italy; Male; Malnutrition; Nursing Homes; Nutrition Assessment; Nutritional Status; Prevalence; Risk Factors; Socioeconomic Factors; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and Gerontologymedicine.diseaseNursing HomesMalnutritionNutrition AssessmentItalySocioeconomic FactorsFemaleGeriatrics and GerontologybusinessNursing homes
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes

2009

Cell death is essential for a plethora of physiological processes, and its deregulation characterizes numerous human diseases. Thus, the in-depth investigation of cell death and its mechanisms constitutes a formidable challenge for fundamental and applied biomedical research, and has tremendous implications for the development of novel therapeutic strategies. It is, therefore, of utmost importance to standardize the experimental procedures that identify dying and dead cells in cell cultures and/or in tissues, from model organisms and/or humans, in healthy and/or pathological scenarios. Thus far, dozens of methods have been proposed to quantify cell death-related parameters. However, no guid…

MESH: Cell DeathcytofluorometryMESH : Microscopy Fluorescenceved/biology.organism_classification_rank.speciesCellMESH: Flow CytometryMESH: Microscopy FluorescenceApoptosisfluorescence microscopyMESH: Eukaryotic CellsAnnexin Vnecrosis0302 clinical medicineEukaryotic Cells/cytologyMitochondrial membrane permeabilizationScanningMESH : ImmunoblottingGeneticsApoptosis; Cell Death; Eukaryotic Cells/cytology; Flow Cytometry; Guidelines as Topic; Humans; Immunoblotting; Microscopy Electron Scanning; Microscopy Fluorescence; Spectrometry Fluorescence0303 health sciencesMicroscopyMESH : Spectrometry FluorescenceMESH: ImmunoblottingCell DeathMESH: Guidelines as Topic//purl.org/becyt/ford/3.1 [https]Bioquímica y Biología MolecularFlow Cytometry3. Good healthTunelMedicina Básicamedicine.anatomical_structureEukaryotic Cellscaspases030220 oncology & carcinogenesis//purl.org/becyt/ford/3 [https]MESH: Spectrometry FluorescenceMESH : Microscopy Electron ScanningProgrammed cell deathautophagyCIENCIAS MÉDICAS Y DE LA SALUDMESH: Microscopy Electron ScanningMESH : Flow CytometrycaspaseImmunoblottingGuidelines as TopicComputational biologyBiologyElectronFluorescenceArticle03 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEmedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyModel organismddc:612mitotic catastropheMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH : Guidelines as Topic030304 developmental biologycell death; Apoptosis; caspase; autophagy; Oxidative stress; fluorescence microscopyMESH: Humansved/biologySpectrometryInterpretation (philosophy)MESH: ApoptosisMESH : Eukaryotic CellsMESH : HumansApoptosis; Eukaryotic Cells; Flow Cytometry; Guidelines as Topic; Humans; Immunoblotting; Microscopy Electron Scanning; Microscopy Fluorescence; Spectrometry Fluorescence; Cell Death; Molecular Biology; Cell Biologyimmunofluorescence microscopyCell BiologySpectrometry FluorescenceMicroscopy FluorescenceOxidative stressMESH : Cell DeathCancer cellMicroscopy Electron ScanningMESH : Apoptosis
researchProduct

Clinical practice guideline for the integrated management of major trauma by the Italian National Institute of Health: process and methods

2021

Background. Major trauma describes serious injuries requiring lifesaving interventions or resulting in long-term disability; it represents about 8% of all deaths worldwide. Specific guidelines can help reduce deaths and disabilities, provided they adhere to high quality and trustworthiness standards. This article aims at introducing the development process of the Istituto Superiore di Sanità, ISS (Italian National Institute of Health) guideline for major trauma integrated management. Methods. We applied the ISS methodological standards including the GRADE-ADOLOPMENT approach for adoption, adaptation, and de novo development of trustworthy guidelines. Results. The scope was formulated by the…

Major trauma.ItalyDelivery of Health Care IntegratedHealthcare decision-makingPractice Guidelines as TopicMajor traumaHumansWounds and InjuriesClinical Practice GuidelineGRADE approachSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheItalian National Guidelines System
researchProduct

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

2020

AbstractAs a result of the successful completion of their respective phase III studies compared with vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved for the treatment and secondary prevention of venous thromboembolism (VTE). These DOACs—apixaban, dabigatran, edoxaban, and rivaroxaban—have subsequently seen a steady uptake among clinicians since their approval. Despite the suitability of DOACs for a broad range of patients, they are not appropriate in certain situations, whereas in others they require additional considerations such as dose reductions. Subanalyses of phase III trials and studies on specific VTE patient populations have been conducted t…

Male0301 basic medicineComorbidity030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicinePregnancyEdoxabanNeoplasmsSecondary PreventionChildspecial populationsAge FactorsVenous ThromboembolismHematologyMiddle AgedTreatment OutcomePractice Guidelines as TopicFemaleKidney Diseasesmedicine.drugAdultmedicine.medical_specialtyMEDLINEHemorrhagecomorbiditiesdirect oral anticoagulantsDabigatran03 medical and health sciencesmedicineHumansLactationDosingIntensive care medicineAgedDose-Response Relationship Drugbusiness.industryPatient SelectionPregnancy Complications HematologicContraindications DrugAnticoagulantsmedicine.diseaseComorbidityReview articleClinical trial030104 developmental biologyClinical Trials Phase III as TopicchemistrybusinessVenous thromboembolismFactor Xa InhibitorsThrombosis and Haemostasis
researchProduct

Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendation…

2020

An accurate knowledge of the epidemiology of community-acquired pneumonia (CAP) is key for selecting appropriate antimicrobial treatments. Very few etiological studies assessed the appropriateness of empiric guideline recommendations at a multinational level. This study aims at the following: (i) describing the bacterial etiologic distribution of CAP and (ii) assessing the appropriateness of the empirical treatment recommendations by clinical practice guidelines (CPGs) for CAP in light of the bacterial pathogens diagnosed as causative agents of CAP. Secondary analysis of the GLIMP, a point-prevalence international study which enrolled adults hospitalized with CAP in 2015. The analysis was l…

Male0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCommunity-acquired pneumonia030106 microbiologyAntimicrobial treatmentPrevalenceGuidelineSettore MED/10 - Malattie Dell'Apparato RespiratorioGuidelinesGlobal Healthmedicine.disease_causeImmunocompromised Host03 medical and health sciences0302 clinical medicineMedical microbiologyCommunity-acquired pneumoniaInternal medicineEpidemiologyStreptococcus pneumoniaePneumonia BacterialPrevalenceHumansMedicine030212 general & internal medicinePractice Patterns Physicians'AgedAged 80 and overbusiness.industryCorrectionGeneral MedicineGuidelineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsCommunity-Acquired InfectionsHospitalizationPneumoniaInfectious DiseasesStreptococcus pneumoniaePractice Guidelines as TopicPseudomonas aeruginosaEtiologyOriginal ArticleFemaleGuideline Adherencebusiness
researchProduct

Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia.

2015

none 22 no Background: Few studies evaluated the clinical outcomes of Community Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP) and Health Care-Associated Pneumonia (HCAP) in relation to the adherence of antibiotic treatment to the guidelines of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) in hospitalized elderly people (65 years or older). Methods: Data were obtained from REPOSI, a prospective registry held in 87 Italian internal medicine and geriatric wards. Patients with a diagnosis of pneumonia (ICD-9 480-487) or prescribed with an antibiotic for pneumonia as indication were selected. The empirical antibiotic regimen was defined t…

MaleAntibiotic regimenGuidelines adherenceSettore MED/09 - Medicina InternaAntibioticsLogistic regressionElderlyCommunity-acquired pneumoniaAntibiotics80 and overElderly peopleAge FactorHospital MortalityAged 80 and overTreatment regimenMedicine (all)Age FactorsOptimal managementAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalization; Internal Medicine; Medicine (all)Anti-Bacterial AgentsHospitalizationTreatment OutcomePractice Guidelines as TopicFemaleGuideline AdherenceHumanmedicine.medical_specialtyLogistic Modelmedicine.drug_classSocio-culturaleantibiotic treatment; guidelines; pneumonia; elderly;Internal medicineRe-hospitalizationAnti-Bacterial AgentmedicineInternal MedicineHumanselderly pmeumonia antibiotics guidelines adherence mortality re-hospitalizationpmeumoniaMortalityIntensive care medicineAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalization; Internal MedicineAgedbusiness.industrySettore MED/09 - MEDICINA INTERNAAntibioticPneumoniamedicine.diseasePneumoniaAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalizationLogistic ModelsAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalizationbusiness
researchProduct

Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics

2018

Abstract Background Acute asthma attack is a frequent condition in children. It is one of the most common reasons for emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high prevalence of asthma in children, and its life-threatening risks. Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over age 2, in ambulatory and emergency department settings. Methods The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving studies in Englis…

MaleAsthma; Asthma attack; Children; GuidelinesPediatricsReviewGuidelineCochrane LibraryIpratropium bromidePediatricsSeverity of Illness Index0302 clinical medicineAnti-Asthmatic AgentsChildChildrenSocieties MedicalPediatriclcsh:RJ1-570PrognosisBronchodilator AgentsEpinephrineTreatment OutcomeInhalationItalyChild PreschoolAmbulatoryAdministrationCombinationPractice Guidelines as TopicDrug Therapy CombinationFemaleHumanmedicine.drugmedicine.medical_specialtyAdolescentPrognosiAsthma attackMEDLINEGuidelinesRisk Assessment03 medical and health sciencesDrug Therapy030225 pediatricsMedicalAdministration InhalationmedicineAnti-Asthmatic AgentHumansAsthma; Asthma attack; Children; Guidelines; Administration Inhalation; Adolescent; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Italy; Male; Pediatrics; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Treatment Outcome; Practice Guidelines as TopicPreschoolBronchodilator AgentAsthmabusiness.industrylcsh:PediatricsEmergency departmentGuidelinemedicine.diseaseAsthma030228 respiratory systemPediatrics Perinatology and Child HealthbusinessSocieties
researchProduct